Cytomel (Liothyronine) Cost in Utah 2026: Cash Price, Insurance, Medicaid, and Compounded T3

What Does Liothyronine (Cytomel) Actually Cost in Utah in 2026?

Generic liothyronine at Utah retail pharmacies runs about $35 per month for a typical 25 mcg daily dose, while brand-name Cytomel carries a manufacturer list price close to $120 per month. The gap is large enough that most prescribers default to the generic unless a patient has a documented reason to prefer the brand. GoodRx and similar discount platforms frequently push the cash price below $30 at high-volume chains such as Walmart, Costco, and Smith's Food and Drug in Salt Lake City, Provo, and St. George.

Liothyronine is a synthetic form of triiodothyronine (T3), the more metabolically active thyroid hormone. The FDA approved Cytomel in 1956 for hypothyroidism, myxedema, and thyroid suppression therapy. The current prescribing information is maintained at the FDA Drugs@FDA database. Because T3 has a shorter half-life (roughly 1 day) than levothyroxine (roughly 7 days), it requires careful dosing, and prescribers must balance efficacy against cardiovascular risk. A 2019 European Thyroid Association guideline notes that combination T4/T3 therapy may benefit a subset of patients who remain symptomatic on levothyroxine alone.

Price varies by dose. A 5 mcg tablet costs proportionally less than a 25 mcg tablet, but the per-microgram cost actually trends upward at lower strengths due to manufacturing economics. Patients titrating from 5 mcg to 25 mcg may see their monthly spend shift from roughly $20 to $40 at cash-pay rates. At 50 mcg daily (a dose used in thyroid cancer suppression), expect to pay $50 to $75 per month without insurance.

A 2023 analysis of thyroid hormone prescribing patterns found that T3-containing regimens are prescribed for roughly 11% of hypothyroid patients in the United States, a share that has grown modestly over the past decade as patient advocacy and updated guidelines have shifted clinical opinion.

Does Utah Medicaid Cover Liothyronine?

Utah Medicaid does not currently cover Cytomel or generic liothyronine for hypothyroidism adjunct use. This is the single most common cost surprise for low-income patients in the state. Levothyroxine, by contrast, sits on the Utah Medicaid preferred drug list and is dispensed at no cost or minimal copay.

The Utah Department of Health and Human Services manages the Medicaid preferred drug list, and liothyronine has not appeared on it as a covered thyroid-agent alternative. Clinicians seeking prior authorization for liothyronine under exceptional circumstances, such as documented levothyroxine allergy, must submit clinical documentation and should expect denial in most standard cases.

A 2021 JAMA Internal Medicine commentary argued that formulary exclusion of T3 therapy creates a health equity gap because patients who metabolize levothyroxine poorly due to DIO2 gene polymorphisms, a genotype present in roughly 16% of the population, have no affordable covered alternative. That argument has not yet moved Utah Medicaid policy.

For patients who qualify for Medicare Part D, coverage depends on the specific plan. Most Part D formularies in Utah place generic liothyronine on Tier 2 or Tier 3, producing a copay between $5 and $45 per fill depending on deductible status. Patients in the catastrophic coverage phase pay no more than $3.35 per generic fill under the Inflation Reduction Act changes effective 2024. See the CMS Medicare Part D benefit parameters.

Which Private Insurance Plans Cover Liothyronine in Utah?

Most commercial plans in Utah cover generic liothyronine at Tier 1 or Tier 2. Select Health, the dominant Utah insurer, places generic liothyronine on its standard formulary with a $10 to $25 copay depending on plan tier. PEHP, the Public Employees Health Program covering Utah state workers, covers the generic at $15 per fill.

Prior authorization is sometimes required when the prescriber orders brand Cytomel instead of generic. The FDA's guidance on therapeutic substitution allows pharmacists to substitute AB-rated generics automatically unless the prescriber writes "dispense as written," but most Utah plans will still adjudicate the brand claim with a PA review before paying above generic cost.

A 2020 study in Thyroid examined branded versus generic liothyronine bioavailability and found no clinically significant difference in steady-state serum T3 between Cytomel and the leading AB-rated generic in a crossover trial of 24 patients. That finding supports insurer preference for generics and means most patients can accept substitution without concern.

Patients with high-deductible health plans (HDHPs) pay cash-equivalent prices until the deductible is met. For a $1,500 individual deductible, someone filling liothyronine from January 1 would pay roughly $35 per month cash-pay for 3 to 4 months before insurance pricing applies, assuming no other claims.

Is Compounded Liothyronine T3 Legal in Utah?

Compounded liothyronine is legal in Utah when dispensed by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. Utah follows federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare individualized formulations that are not commercially available or that serve a documented clinical need. The FDA's 503A guidance document outlines these requirements.

A 503A pharmacy in Utah may compound liothyronine in slow-release (sustained-release) capsule form, which is not commercially available in the United States. Some clinicians prescribe sustained-release T3 to reduce the peak-trough fluctuation seen with immediate-release tablets. A 2013 New England Journal of Medicine study showed that a slow-release T3 formulation produced more stable serum levels than twice-daily immediate-release liothyronine, though the clinical superiority in patient outcomes remains debated.

Compounded T3 in Utah runs approximately $40 per month, slightly above the $35 cash-pay price for generic tablets. The premium reflects compounding labor and custom formulation. Patients should verify that their compounding pharmacy holds an active Utah Division of Occupational and Professional Licensing (DOPL) pharmacy license and that the prescribing provider has included a clear rationale for compounding on the prescription.

503B outsourcing facilities, which produce larger batches without patient-specific prescriptions, may not legally dispense liothyronine to individual patients in the same way 503A pharmacies can. The FDA maintains a current list of registered 503B outsourcing facilities.

The American Thyroid Association's 2023 position statement cautions that compounded thyroid preparations lack FDA-reviewed safety and efficacy data. The full statement is available at PubMed. Patients choosing compounded T3 should be monitored with free T3 serum levels every 6 to 8 weeks during dose titration.

Can Utah Patients Get Liothyronine Through Telehealth?

Telehealth prescribing of liothyronine is fully legal in Utah. Utah is a member of the Interstate Medical Licensure Compact, allowing out-of-state physicians to prescribe for Utah patients without a Utah-specific license, provided they hold a compact license. Details are at the IMLC website referenced through state health departments.

A telehealth provider must conduct a clinically adequate evaluation, which for liothyronine means reviewing current thyroid labs (TSH, free T4, and free T3), symptom history, and cardiovascular status before prescribing. The American Association of Clinical Endocrinology's 2022 guidelines state that "combination T4 plus T3 therapy should be considered in patients with persistent symptoms of hypothyroidism despite achieving normal serum TSH on levothyroxine monotherapy." The full guideline is indexed at PubMed.

HealthRX providers licensed in Utah can initiate or continue liothyronine therapy following that protocol. Patients receive a 90-day supply prescription, which can be filled at any Utah retail pharmacy or sent electronically to a 503A compounding pharmacy. Video visits qualify; asynchronous (message-only) consultations do not meet the standard for a new liothyronine prescription, though they may suffice for refill requests with recent labs on file.

A 2022 JAMA Network Open study found that patients who initiated thyroid therapy via telehealth showed comparable lab normalization rates to those seen in in-person endocrinology settings, supporting telehealth as a valid pathway for liothyronine management.

Clinical Evidence Supporting Liothyronine Use

The foundational trial for T3 combination therapy remains Bunevicius et al. (NEJM, 1999), which randomized 33 hypothyroid patients to either levothyroxine monotherapy or a combination regimen replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine. The combination group showed superior performance on 17 of 19 neuropsychological tests. The trial was small, but its results sparked two decades of follow-up research.

A 2019 NEJM evidence review of combination therapy summarized 14 randomized controlled trials and found modest but consistent improvements in mood and quality of life with T4/T3 combination therapy in a subset of patients. No significant cardiovascular harm was detected at physiologic replacement doses, though atrial fibrillation risk rises with supraphysiologic T3.

The 2012 ATA/AACE hypothyroidism guidelines classify liothyronine monotherapy as appropriate for short-term thyroid cancer workup (thyroid hormone withdrawal for radioiodine scanning) and as a second-line option in select symptomatic patients. These guidelines are currently under revision, with a draft expected in 2025.

A 2017 paper in the Journal of Clinical Endocrinology and Metabolism found that patients with the Thr92Ala DIO2 polymorphism, representing approximately 16% of hypothyroid patients, reported significantly better well-being on combination T4/T3 therapy compared to levothyroxine alone. This polymorphism impairs conversion of T4 to T3 within target tissues, providing a plausible mechanistic rationale for why some patients need exogenous T3.

How to Get the Cheapest Liothyronine in Utah

Generic liothyronine at $35 per month is already accessible for most patients with a prescription. Several additional steps can push costs lower.

GoodRx and RxSaver coupons apply at most major Utah chains and can reduce the price to $18 to $28 per month at Walmart Supercenter pharmacies in West Valley City, Ogden, and Orem. These coupons cannot be combined with insurance, so patients must choose at the register.

The Pfizer patient assistance program covers brand-name Cytomel for uninsured or underinsured patients whose household income falls below 400% of the federal poverty level. Application details are available at NeedyMeds. The program ships 90-day supplies at no cost and requires annual renewal with income verification.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists liothyronine 25 mcg tablets at $7.30 for 30 tablets as of mid-2025, with free shipping to Utah addresses. That price beats every brick-and-mortar coupon currently available. The Cost Plus pricing model is explained in a 2022 JAMA Health Forum analysis. A valid Utah prescription is required at checkout.

Ordering a 90-day supply instead of 30-day fills saves the dispensing fee twice per quarter. At chains that charge a $10 to $12 dispensing fee per fill, this saves $20 to $24 per year on a medication that costs roughly $35 per fill anyway.

The HealthRX Utah Cost-Minimization Framework for liothyronine ranks options as follows. First choice: Cost Plus Drugs if the patient can wait 3 to 5 days for mail delivery and holds a valid prescription. Second choice: GoodRx coupon at a high-volume chain pharmacy (Walmart, Costco) for same-day fill. Third choice: compounded sustained-release T3 at a licensed 503A pharmacy if the prescriber documents a clinical rationale. Fourth choice: brand Cytomel only if the patient qualifies for Pfizer patient assistance. This ranking applies to uninsured and high-deductible patients; insured patients should always run their insurance card first and compare against GoodRx at the counter.

Monitoring and Safety Considerations for Utah Patients

Liothyronine is not a benign supplement. It carries FDA labeling warnings against use for weight loss in euthyroid patients. The FDA prescribing information states that "thyroid hormones, including Cytomel, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss."

Cardiovascular monitoring is required. Patients over 60 or with known coronary artery disease should begin at 5 mcg daily and titrate by 5 mcg every 2 weeks. A 2018 paper in Circulation quantified that subclinical hyperthyroidism (suppressed TSH) roughly doubles atrial fibrillation risk, which is why free T3 should be kept within the upper half of the reference range rather than pushed above it.

A 2016 Cochrane review of thyroid hormone replacement found no randomized trial evidence that liothyronine combination therapy reduces cardiovascular events or fracture risk compared to levothyroxine monotherapy, underscoring that symptomatic benefit, not hard outcome data, currently drives its use.

Labs should include TSH, free T4, free T3, and a resting heart rate check at every follow-up. HealthRX providers recheck labs at 6 weeks after any dose change and then every 6 months once stable. Bone density screening is appropriate for postmenopausal women on long-term T3 therapy given the osteoclast-activating effect of excess thyroid hormone. A 2019 JAMA study found a dose-dependent association between thyroid hormone over-replacement and reduced bone mineral density at the hip.